British Journal Pharmacology

Barann M, Molderings G, Brass M, Bonisch H, Urban BW, Gothert M. (2002) Direct inhibition by cannab-inoids of human SHT3A receptors probable involvement of an allosteric modulatory site. British Journal Pharmacology 137 589-596. 

Clubley, M., Bye, C. E., Henson, T. A., Peck, A. W. and Riddington, C. J., Effects of caffeine and cyclizine alone and in combination on human performance, subjective effects and EEG activity. British Journal of Clinical Pharmacology 7 157-63, 1979. 

Bruce, M., Scott, N., Lader, M. and Marks, V., The psychopharmacological and electrophysiological effects of a single dose of caffeine in healthy human subjects. British Journal of Clinical Pharmacology 22, 81-87, 1986. 

DeAngelis, Catherine D. and Phil B. Fontanarosa, Conflicts over Conflicts of Interest , Journal of the American Medical Association (2009) http / /jama, ama-assn.org/misc/jed900i2pap Ei E3.pdf de Craen, Anton J. M., D. E. Moerman, S. H. Heisterkamp, G. N. J. Tytgat, J. G. Tijssen andj. Kleijnen, Placebo Effect in the Treatment of Duodenal Ulcer , British Journal of Clinical Pharmacology 48 (1999) 853-60... 

Ashton H, Savage RD, Telford R, Thompson JW and Watson DW (1972). The effects of cigarette smoking on the response to stress in a driving simulator. British Journal of Pharmacology, 45, 546-556. 

Badawy AA-B and Evans M (1982). Inhibition of rat liver tryptophan pyrrolase and elevation of brain tryptophan concentrations by acute administration of small doses of antidepressants. British Journal of Pharmacology, 77, 59-67. 

Campbell M, Young PI, Bateman DN, Smith JM and Thomas SHL (1999). The use of atypical antipsychotics in the management of schizophrenia. British Journal of Clinical Pharmacology, 4,1, 13-22. 

Hirst RA, Lambert DG and Notcutt WG (1998). Pharmacology and potential therapeutic uses of cannabis. British Journal of Anaesthesia, 81, 77-84. 

Holden-Dye, L., Brownlee, D.J.A. and Walker, R.J. (1997) The effects of the peptide KPNFIRFamide (PF4) on the somatic muscle cells of the parasitic nematode Ascaris suum. British Journal of Pharmacology 120, 379—386. 

Martin, R.J. (1980) The effect of y-aminobutyric acid on the input conductance and membrane potential of Ascaris muscle. British Journal of Pharmacology 71, 99-106. 

Robertson, S.J. and Martin, R.J. (1993) Levamisole-activated single-channel currents from muscle of the nematode parasite Ascaris suum. British Journal of Pharmacology 108, 170-178. 

Bates, S. and Weitz, J. 2005. New anticoagulants beyond heparin, low molecular weight heparin and warfarin. British Journal of Pharmacology 144(8), 1017-1028. 

Suessbrich, H., Schonherr, R., Heinemann, S.H., Attali, B., Lang, F. and Busch, A.E. (1997) The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. British Journal of Pharmacology, 120, 968-974. 

Mitcheson, J.S. (2003) Drug binding to HERG channels evidence for a nonaromatic binding site for fluvoxamine. British Journal of Pharmacology, 139, 883-884. 

C. R., Klemens, C.A., Gillman, B.M., Anderson, C.L., Holzem, KM., Delisle, B.P., Anson, B.D., Makielski, J.C. and January, C.T. (2006) Drug-induced long QT syndrome hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. British Journal of Pharmacology, 149, 481 189. 

Allen, M.J., Nichols, D.J. and Oliver, S.D. (2000) The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. British Journal of Clinical Pharmacology, 50, 247-253. 

Gessner, G. and Heinemann, S.H. (2003) Inhibition of hEAGl and hERGl potassium channels by clofilium and its tertiary analogue LY97241. British Journal of Pharmacology, 138, 161-171. 

Bertilsson, L., Carrillo, J.A., Dahl, M.L., Llerena, A., Aim, C., Bondesson, U., Lindstrom, L., Rodriguez dela Rubia, I., Ramos, S. and Benitez, J. (1994) Clozapine disposition covaries with CYP1A2 activity determined hy a caffeine test. British Journal of Clinical Pharmacology, 38 (5), 471 173. 

Nakajima, M., Kohayashi, K., Shimada, N., Tokudome, S., Yamamoto, T. and Kuroiwa, Y. (1998) Involvement of CYP1A2 in mexiletine metabolism. British Journal of Clinical Pharmacology, 46 (1), 55-62. 

Ha, H.R., Chen, J., Freiburghaus, A.U. and Follath, F. (1995) Metabolism of theophylline by cDNA-expressed human cytochromes P-450. British Journal of Clinical Pharmacology, 39 (3), 321-326. 

Kenworthy, K.E., Bloomer, J.C., Clarke, S.E. and Houston, J.B. (1999) CYP3A4 drug interactions correlation of 10 in vitro probe substrates. British Journal of Clinical Pharmacology, 48 (5), 716-727. 

Ito, K., Brown, H.S. and Houston, J.B. (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. British Journal of Clinical Pharmacology, 57 (4), 473—486. 

Tarrus, E., Cami, J., Roberts, D.J., Spickett, R.G., Celdran, E. and Segura, J. (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. British Journal of Clinical Pharmacology, 23 (1), 9-18. 

B. K. (1967) Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. British Journal of Pharmacology and Chemotherapy, 29, 150. 

Goldstein, J.A. (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology, 52, 349-355. 

Renes, J., deVries, E.G., Nienhuis, E.F., Jansen, P.L. and Muller, M. (1999) ATP-and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. British Journal of Pharmacology, 126, 681-688. 

Mayer, U., Wagenaar, E., Beijnen, J.H., Smit, J.W., Meijer, D.K., van Asperen, J., Borst, P. and Schinkel, A.H. (1996) Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr la P-glycoprotein. British Journal of Pharmacology, 119, 1038-1044. 

Drescher, S., Schaeffeler, E., Hitzl, M., Hofmann, U., Schwab, M., Brinkmann, U., Eichelbaum, M. and Fromm, M.F. (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. British Journal of Clinical Pharmacology, 53, 526-534. 

Rasmussen M.A. Colding-Jorgensen, M. Hansen, L.T. Bro, R. Multivariate evaluation of pharmacological responses in early clinical trials - A study of rIL-21 in the treatment of patients with metastatic melanoma. British Journal of Clinical Pharmacology, 2010, 69 (4), 379-390. 

A very useful review of the history and development of the Declaration of Helsinki in the last four decades from its evolution from the principles enunciated in the Nuremberg Code of 1947 to the current version has been published in the British Journal of Clinical Pharmacology and is recommended reading, it includes the texts of the various versions of the Declaration. 

Tse, H.-F., Zhang, S. and Li, G.-R. (2008) The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-a-go-go-related gene (hERG) potassium channels. British Journal of Pharmacology, 81, 1-9. 

Scherer, C.R., Lerche, C., Decher, N., Dennis, A.T., Maier, P., Picker, E., Busch, A.E., Wollnik, B. and Steinmeyer, K. (2002) The antihistamine fexofenadine does not affect l(Kr) currents in a case report of drug-induced cardiac arrhythmia. British Journal of Pharmacology, 137, 892-900. 

Ekins, S., Mesties, J. and Testa, B. (2007) In silico pharmacology for drug discovery methods for virtual ligand screening and profiling. British Journal of Pharmacology, 152, 9-20. 

---